REG-Bioventix Plc: Issue of Equity <Origin Href="QuoteRef">BVXP.L</Origin>

BioventixAnnouncement

14/07/2016 09:15

Bioventix plc

(“Bioventix” or the “Company”)

Issue of Equity

Bioventix plc (AIM: BVXP) announces that it has today applied for 47,725
ordinary shares of 5 pence each (the “Option Shares”) to be admitted to
trading on AIM (“Admission”). It is expected that Admission will occur and
that dealings will commence in the Option Shares on 18 July 2016.

The Option Shares are being issued pursuant to the exercise of options by
employees of the Company. The Option Shares will rank pari passu with the
existing ordinary shares of 5 pence each in the capital of the Company
("Ordinary Shares").

The total number of Ordinary Shares in issue following Admission will be
5,098,656 and the Company holds no shares in treasury. Therefore the total
number of Ordinary Shares with voting rights in the Company will be 5,098,656.

The above figure of 5,098,656 may be used by shareholders as the denominator
for the calculations by which they will determine if they are required to
notify their interest in, or a change to their interest in, Bioventix under
the FCA’s Disclosure and Transparency Rules.

For further information please contact:

 Bioventix plc Peter Harrison                         Chief Executive Officer              Tel: 01252 728 001  
                                                                                                               
 finnCap Ltd Geoff Nash/Simon Hicks Stephen Norcross  Corporate Finance Corporate Broking  Tel: 020 7220 0500  

About Bioventix plc:

Bioventix (www.bioventix.com) specialises in the development and commercial
supply of high-affinity monoclonal antibodies with a primary focus on their
application in clinical diagnostics, such as in automated immunoassays used in
blood testing.  The antibodies created at Bioventix are generated in sheep
and are of particular benefit where the target is present at low concentration
and where conventional monoclonal or polyclonal antibodies have failed to
produce a suitable reagent.  Bioventix currently offers a portfolio of
antibodies to customers for both commercial use and R&D purposes, for the
diagnosis or monitoring of a broad range of conditions, including heart
disease, cancer, fertility, thyroid function and drug abuse.  Bioventix
currently supplies antibody products and services to the majority of
multinational clinical diagnostics companies.  Bioventix is based in Farnham,
UK and its shares are traded on AIM under the symbol BVXP.



Copyright (c) 2016 PR Newswire Association,LLC. All Rights Reserved